Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and Novo Nordisk A/S. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$788.91 +17.16 (+2.22%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$788.70 -0.21 (-0.03%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $799, reflecting a strong market position and investor confidence in the company's future growth.
  • Eli Lilly and Co reported a significant revenue increase of over 45% compared to the same quarter last year, indicating robust business performance and demand for its products.
  • The company has a high return on equity of over 85%, suggesting effective management and a strong ability to generate profits from shareholders' investments.

Cons of Eli Lilly and Company

  • The company recently missed earnings expectations, reporting an EPS of $3.34 compared to the consensus estimate of $4.64, which may raise concerns about future profitability.
  • Despite strong revenue growth, the high P/E ratio of around 65 suggests that the stock may be overvalued, which could lead to price corrections.
  • Analysts have mixed ratings, with some downgrading their outlook, indicating uncertainty in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$731.42 billion
P/E Ratio
64.19
Consensus Rating
Moderate Buy
Consensus Price Target
$1,012.56 (+28.3% Upside)
Volume
3.25 million shares
Average Volume
3.67 million shares
Today's Range
$772.16
$796.04
50-Day Range
$713.99
$818.56
52-Week Range
$677.09
$972.53
Dividend Yield
0.78%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$164.78 +9.61 (+6.19%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$164.48 -0.30 (-0.18%)
As of 04:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $156.91, which may present a buying opportunity for investors looking for value in a stable company.
  • Johnson & Johnson recently reported strong quarterly earnings, with earnings per share (EPS) of $2.77, exceeding expectations, indicating robust financial health.
  • The company has a solid market capitalization of approximately $376 billion, reflecting its significant presence and stability in the healthcare sector.

Cons of Johnson & Johnson

  • Despite its strong performance, the stock has a relatively high price-to-earnings (P/E) ratio of 17.40, which may suggest that it is overvalued compared to its earnings.
  • Analysts have mixed ratings on the stock, with several recent downgrades, indicating uncertainty about its future performance.
  • The company has a beta of 0.41, suggesting lower volatility compared to the market, which may limit potential high returns for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$373.35 billion
P/E Ratio
18.33
Consensus Rating
Moderate Buy
Consensus Price Target
$171.00 (+3.8% Upside)
Volume
22.13 million shares
Average Volume
8.12 million shares
Today's Range
$159.80
$166.12
50-Day Range
$146.39
$164.78
52-Week Range
$140.68
$169.99
Dividend Yield
3.35%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$190.53 +4.14 (+2.22%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$190.51 -0.02 (-0.01%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $190, which is significantly lower than its twelve-month high, suggesting potential for price appreciation.
  • AbbVie recently reported strong quarterly earnings, with earnings per share of $2.46, exceeding expectations and indicating robust financial health.
  • The company has a solid revenue growth of 8.4% year-over-year, reflecting its ability to expand its market presence and product offerings.

Cons of AbbVie

  • AbbVie has a high dividend payout ratio of 279.15%, which may raise concerns about the sustainability of its dividend payments in the long term.
  • The stock has a relatively high price-to-earnings (P/E) ratio of 81.31, suggesting that it may be overvalued compared to its earnings, which could deter value-focused investors.
  • Despite positive earnings, the company's net margin of 7.31% is relatively low, indicating potential challenges in maintaining profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$329.24 billion
P/E Ratio
81.08
Consensus Rating
Moderate Buy
Consensus Price Target
$211.29 (+10.9% Upside)
Volume
6.20 million shares
Average Volume
6.30 million shares
Today's Range
$186.50
$191.39
50-Day Range
$177.30
$194.96
52-Week Range
$163.81
$218.66
Dividend Yield
3.52%
Novo Nordisk A/S stock logo

4. Novo Nordisk A/S NYSE:NVO

$67.08 -0.14 (-0.21%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$66.40 -0.68 (-1.01%)
As of 04:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $71, reflecting a strong market position and investor confidence in the company's growth potential.
  • Recent earnings reports indicate that Novo Nordisk has consistently met consensus estimates, showcasing its financial stability and operational efficiency.
  • The company has a high return on equity, suggesting effective management and profitability, which can be attractive to investors looking for solid returns.

Cons of Novo Nordisk A/S

  • The stock has experienced fluctuations, with a one-year high of $143.49 and a low of $57.00, indicating potential volatility that could concern risk-averse investors.
  • Recent reports show that some institutional investors have reduced their stakes significantly, which may suggest a lack of confidence in the company's short-term prospects.
  • The company's debt-to-equity ratio is relatively high, which could indicate that it is relying on borrowed funds for growth, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$300.14 billion
P/E Ratio
19.85
Consensus Rating
Hold
Consensus Price Target
$112.00 (+67.0% Upside)
Volume
5.59 million shares
Average Volume
7.33 million shares
Today's Range
$66.99
$68.04
50-Day Range
$64.32
$81.07
52-Week Range
$57.00
$139.74
Dividend Yield
2.44%
UnitedHealth Group stock logo

5. UnitedHealth Group NYSE:UNH

$292.20 +0.49 (+0.17%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$293.35 +1.16 (+0.40%)
As of 04:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The current stock price is around $299.70, which may present a buying opportunity for investors looking for value.
  • UnitedHealth Group has a strong annualized dividend of $8.84, providing a yield of 2.94%, which can be attractive for income-focused investors.
  • Analysts have a consensus rating of "Moderate Buy" with an average price target of $415.00, indicating potential upside from the current price.

Cons of UnitedHealth Group

  • Recent downgrades from several analysts, including a reduction in price targets, may indicate a lack of confidence in short-term performance.
  • The stock has experienced volatility, with a 12-month high of $630.73 and a low of $248.88, suggesting potential instability.
  • UnitedHealth Group's debt-to-equity ratio of 0.71 indicates a moderate level of debt, which could pose risks if market conditions worsen.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$264.62 billion
P/E Ratio
12.24
Consensus Rating
Moderate Buy
Consensus Price Target
$394.43 (+35.0% Upside)
Volume
9.68 million shares
Average Volume
7.72 million shares
Today's Range
$290.75
$295.99
50-Day Range
$273.96
$385.74
52-Week Range
$248.88
$630.73
Dividend Yield
3.03%
Novartis stock logo

6. Novartis NYSE:NVS

$118.44 -1.23 (-1.03%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$117.91 -0.53 (-0.44%)
As of 04:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $123, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Novartis AG has received a "strong-buy" rating from analysts, suggesting strong confidence in the company's future performance.
  • The company reported earnings per share that exceeded consensus estimates, indicating strong financial health and operational efficiency.

Cons of Novartis

  • Despite recent positive ratings, there are still analysts who have rated the stock with a sell or hold, indicating mixed opinions on its future performance.
  • The company has a relatively high debt-to-equity ratio, which could indicate potential financial risk if not managed properly.
  • Market volatility can impact stock performance, and recent trading volumes suggest fluctuations that may concern some investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$252.79 billion
P/E Ratio
18.51
Consensus Rating
Hold
Consensus Price Target
$123.67 (+4.4% Upside)
Volume
2.50 million shares
Average Volume
1.59 million shares
Today's Range
$117.80
$119.55
50-Day Range
$105.18
$123.83
52-Week Range
$96.06
$124.83
Dividend Yield
2.17%
Abbott Laboratories stock logo

7. Abbott Laboratories NYSE:ABT

$131.79 +0.30 (+0.23%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$131.27 -0.52 (-0.40%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • Abbott Laboratories recently reported earnings per share (EPS) of $1.09, surpassing analyst expectations, indicating strong financial performance.
  • The company has a robust net margin of nearly 32%, suggesting efficient management and profitability.
  • With a current stock price around $131.56, the shares are positioned well within a market cap of approximately $228.90 billion, reflecting solid market confidence.

Cons of Abbott Laboratories

  • Despite strong earnings, the company's revenue of $10.36 billion fell slightly short of analyst expectations, which could raise concerns about future growth.
  • The stock has experienced fluctuations, with a one-year low of $99.71 and a high of $141.23, indicating potential volatility.
  • Insider selling activity, such as the recent sale of 2,600 shares by a director, may signal a lack of confidence among insiders.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$228.77 billion
P/E Ratio
17.09
Consensus Rating
Moderate Buy
Consensus Price Target
$144.33 (+9.5% Upside)
Volume
9.89 million shares
Average Volume
6.14 million shares
Today's Range
$130.31
$133.02
50-Day Range
$128.45
$138.13
52-Week Range
$99.71
$141.23
Dividend Yield
1.79%
AstraZeneca stock logo

8. AstraZeneca NASDAQ:AZN

$70.08 -0.24 (-0.34%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$70.24 +0.17 (+0.24%)
As of 04:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $71, which reflects a stable market position and potential for growth.
  • AstraZeneca has received an "outperform" rating from analysts, indicating strong confidence in its future performance.
  • Institutional investors hold approximately 20.35% of AstraZeneca's stock, suggesting a solid backing from major financial entities.

Cons of AstraZeneca

  • The stock has experienced fluctuations, with a recent trading down of about 0.5%, which may indicate volatility.
  • Despite positive ratings, there is only one hold rating among analysts, suggesting some caution in the market.
  • The P/E ratio is around 28.57, which may be considered high, indicating that the stock could be overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$218.08 billion
P/E Ratio
28.14
Consensus Rating
Moderate Buy
Consensus Price Target
$89.00 (+27.0% Upside)
Volume
3.54 million shares
Average Volume
5.26 million shares
Today's Range
$69.85
$70.69
50-Day Range
$66.23
$75.00
52-Week Range
$61.24
$87.68
Dividend Yield
2.93%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$82.44 +0.93 (+1.13%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$82.58 +0.14 (+0.16%)
As of 04:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $83.80, which reflects a stable market position and potential for growth.
  • Merck recently reported earnings per share that exceeded analyst expectations, indicating strong financial performance and effective management.
  • The company has a solid dividend yield of approximately 3.87%, providing a reliable income stream for investors.

Cons of Merck & Co., Inc.

  • The company's revenue has shown a slight decline year-over-year, which may raise concerns about future growth prospects.
  • Some analysts have downgraded their ratings, reflecting caution regarding Merck's market performance and potential challenges ahead.
  • Merck's stock has experienced volatility, with a 52-week high of $129.03 and a low of $73.31, indicating potential risks for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$204.70 billion
P/E Ratio
12.00
Consensus Rating
Hold
Consensus Price Target
$108.69 (+31.8% Upside)
Volume
11.52 million shares
Average Volume
13.41 million shares
Today's Range
$81.46
$82.64
50-Day Range
$73.46
$84.06
52-Week Range
$73.31
$128.73
Dividend Yield
3.97%
Intuitive Surgical stock logo

10. Intuitive Surgical NASDAQ:ISRG

$512.64 +0.41 (+0.08%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$513.43 +0.79 (+0.16%)
As of 04:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $528, which reflects a strong market position and potential for growth.
  • Intuitive Surgical, Inc. reported a quarterly earnings per share (EPS) of $1.81, exceeding analyst expectations, indicating robust financial performance.
  • The company has a high net margin of 28.41%, suggesting efficient operations and profitability, which can lead to higher returns for investors.

Cons of Intuitive Surgical

  • The price-to-earnings (P/E) ratio is around 77.44, which is relatively high, suggesting that the stock may be overvalued compared to its earnings.
  • Insider selling has been observed, with executives selling shares, which could indicate a lack of confidence in the stock's future performance.
  • The stock has a beta of 1.64, indicating higher volatility compared to the market, which may pose risks for conservative investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$183.59 billion
P/E Ratio
75.17
Consensus Rating
Moderate Buy
Consensus Price Target
$592.86 (+15.6% Upside)
Volume
1.86 million shares
Average Volume
1.68 million shares
Today's Range
$506.21
$515.14
50-Day Range
$509.36
$565.94
52-Week Range
$413.82
$616.00
Dividend Yield
N/A
Thermo Fisher Scientific stock logo

11. Thermo Fisher Scientific NYSE:TMO

$416.42 -1.58 (-0.38%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$416.69 +0.27 (+0.07%)
As of 04:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $429, reflecting a strong position in the market.
  • The company reported a solid earnings per share (EPS) of $5.15 for the latest quarter, exceeding expectations, which indicates robust financial health and operational efficiency.
  • Thermo Fisher Scientific Inc. has a return on equity of 17.15%, suggesting effective management and a strong ability to generate profits from shareholders' equity.

Cons of Thermo Fisher Scientific

  • The price-to-earnings (P/E) ratio is 24.32, which may suggest that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider ownership is relatively low at 0.33%, which could indicate a lack of confidence from executives in the company's future performance.
  • Recent analyst ratings have shown some downward adjustments in target prices, which may reflect concerns about future growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$157.79 billion
P/E Ratio
24.42
Consensus Rating
Moderate Buy
Consensus Price Target
$600.30 (+44.2% Upside)
Volume
2.76 million shares
Average Volume
2.00 million shares
Today's Range
$413.78
$420.55
50-Day Range
$390.17
$435.02
52-Week Range
$385.46
$627.88
Dividend Yield
0.41%
Amgen stock logo

12. Amgen NASDAQ:AMGN

$299.02 +6.51 (+2.23%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$298.51 -0.51 (-0.17%)
As of 04:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Market Capitalization
$157.28 billion
P/E Ratio
27.28
Consensus Rating
Hold
Consensus Price Target
$307.82 (+2.9% Upside)
Volume
1.88 million shares
Average Volume
2.83 million shares
Today's Range
$292.33
$299.34
50-Day Range
$262.28
$300.37
52-Week Range
$253.30
$346.85
Dividend Yield
3.25%
Boston Scientific stock logo

13. Boston Scientific NYSE:BSX

$103.12 -0.36 (-0.35%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$102.78 -0.33 (-0.32%)
As of 04:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The stock has received multiple "buy" ratings from analysts, indicating strong confidence in its future performance.
  • Recent earnings reports show that Boston Scientific Co. exceeded consensus estimates for earnings per share, suggesting robust financial health.
  • The current stock price is around $102, which is near its 52-week high, reflecting positive market sentiment.

Cons of Boston Scientific

  • The stock has a high P/E ratio, which may indicate that it is overvalued compared to its earnings.
  • Insider selling has been observed, with executives reducing their holdings, which could signal a lack of confidence in the company's short-term prospects.
  • The stock's beta of 0.68 suggests lower volatility compared to the market, which may limit potential gains during bullish market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$153.09 billion
P/E Ratio
75.27
Consensus Rating
Buy
Consensus Price Target
$116.09 (+12.6% Upside)
Volume
9.26 million shares
Average Volume
6.72 million shares
Today's Range
$102.59
$104.29
50-Day Range
$98.43
$107.45
52-Week Range
$71.88
$107.53
Dividend Yield
N/A
Stryker stock logo

14. Stryker NYSE:SYK

$390.65 +0.06 (+0.01%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$390.75 +0.10 (+0.03%)
As of 07/16/2025 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • Stryker Co. reported earnings per share (EPS) of $2.84 for the latest quarter, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
  • The company has shown a significant revenue increase of approximately 11.9% compared to the same quarter last year, suggesting robust demand for its products and services.
  • With a current stock price around $400, Stryker Co. is positioned well in the market, reflecting investor confidence and potential for appreciation.

Cons of Stryker

  • The company's dividend payout ratio is currently at 45.41%, which, while sustainable, may limit the funds available for reinvestment into growth opportunities.
  • Insider selling activity, such as the recent sale of 200,000 shares by a director, could signal a lack of confidence in the stock's short-term performance.
  • Despite strong revenue growth, the competitive landscape in the medical technology sector is intense, which could impact future profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$149.08 billion
P/E Ratio
52.79
Consensus Rating
Moderate Buy
Consensus Price Target
$428.55 (+9.7% Upside)
Volume
1.07 million shares
Average Volume
1.35 million shares
Today's Range
$385.93
$391.42
50-Day Range
$373.22
$396.38
52-Week Range
$314.93
$406.19
Dividend Yield
0.86%
Pfizer stock logo

15. Pfizer NYSE:PFE

$24.59 -0.02 (-0.09%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$24.69 +0.10 (+0.41%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $25.84, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Pfizer Inc. has a strong dividend yield of approximately 6.73%, providing a steady income stream for investors, which is particularly attractive in a low-interest-rate environment.
  • The company has a robust pipeline of products, including recent advancements in COVID-19 treatments and vaccines, which could drive future revenue growth.

Cons of Pfizer

  • The company's revenue has decreased by 7.8% compared to the same quarter last year, which may raise concerns about its growth trajectory.
  • Pfizer Inc. has a high dividend payout ratio of 124.64%, suggesting that it may be paying out more in dividends than it earns, which could be unsustainable in the long run.
  • Recent analyst ratings show a mix of hold and neutral ratings, indicating uncertainty among experts regarding the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$139.92 billion
P/E Ratio
17.82
Consensus Rating
Hold
Consensus Price Target
$28.55 (+16.1% Upside)
Volume
44.17 million shares
Average Volume
41.78 million shares
Today's Range
$24.53
$24.96
50-Day Range
$22.01
$25.77
52-Week Range
$20.92
$31.54
Dividend Yield
6.99%
Danaher stock logo

16. Danaher NYSE:DHR

$193.40 +0.54 (+0.28%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$194.68 +1.28 (+0.66%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $248, which reflects a strong market position and potential for growth.
  • Danaher Co. recently reported quarterly earnings that exceeded analyst expectations, indicating robust financial health and operational efficiency.
  • The company has a solid market capitalization of approximately $147.51 billion, suggesting stability and investor confidence.

Cons of Danaher

  • The stock has a relatively high PE ratio, which may indicate that it is overvalued compared to its earnings, posing a risk for potential investors.
  • Recent price target adjustments by analysts suggest some uncertainty in the stock's future performance, with targets being lowered by several firms.
  • Danaher Co. has a beta of 0.77, indicating lower volatility compared to the market, which may limit potential high returns for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$138.02 billion
P/E Ratio
37.55
Consensus Rating
Moderate Buy
Consensus Price Target
$248.43 (+28.5% Upside)
Volume
2.66 million shares
Average Volume
3.51 million shares
Today's Range
$191.15
$194.28
50-Day Range
$184.79
$205.55
52-Week Range
$171.00
$281.70
Dividend Yield
0.66%
Gilead Sciences stock logo

17. Gilead Sciences NASDAQ:GILD

$109.85 +0.79 (+0.72%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$109.18 -0.67 (-0.61%)
As of 07/16/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The current stock price is around $112, reflecting a strong performance in the market.
  • Gilead Sciences, Inc. reported earnings per share of $1.81, exceeding analysts' expectations, indicating robust financial health.
  • The company has a high return on equity of 51.93%, suggesting effective management and profitability.

Cons of Gilead Sciences

  • The company's revenue has shown a slight decline of 0.3% compared to the same quarter last year, which may raise concerns about growth.
  • Insider selling has occurred, with the CEO recently selling 10,000 shares, which could signal a lack of confidence in the stock's future performance.
  • Despite a strong earnings report, the revenue fell short of analysts' expectations, indicating potential challenges in meeting future growth targets.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$135.66 billion
P/E Ratio
23.13
Consensus Rating
Moderate Buy
Consensus Price Target
$111.38 (+1.4% Upside)
Volume
3.96 million shares
Average Volume
7.68 million shares
Today's Range
$108.57
$110.72
50-Day Range
$96.86
$114.54
52-Week Range
$70.78
$119.96
Dividend Yield
2.90%
Vertex Pharmaceuticals stock logo

18. Vertex Pharmaceuticals NASDAQ:VRTX

$469.55 +5.35 (+1.15%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$470.00 +0.45 (+0.10%)
As of 04:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $454, reflecting a strong market presence and investor interest in the company.
  • Vertex Pharmaceuticals has shown resilience with a market capitalization exceeding $116 billion, indicating robust investor confidence and financial stability.
  • Recent earnings reports indicate a revenue of approximately $2.77 billion for the latest quarter, showcasing the company's ability to generate significant income.

Cons of Vertex Pharmaceuticals

  • The company reported a negative return on equity, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Vertex Pharmaceuticals has a negative net margin, indicating that the company is currently spending more than it earns, which could affect future growth prospects.
  • Recent earnings missed analysts' expectations, which may signal potential challenges in meeting market forecasts and could lead to decreased investor confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$119.21 billion
P/E Ratio
-119.78
Consensus Rating
Moderate Buy
Consensus Price Target
$511.71 (+9.0% Upside)
Volume
785,364 shares
Average Volume
1.42 million shares
Today's Range
$465.10
$470.94
50-Day Range
$421.16
$479.53
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Sanofi stock logo

19. Sanofi NASDAQ:SNY

$48.52 +0.40 (+0.83%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$48.58 +0.06 (+0.13%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has received multiple upgrades from analysts, with a consensus rating of "Buy" and an average target price of around $61.50, indicating strong potential for price appreciation.
  • The current stock price is approximately $48.89, which is below the average target price set by analysts, suggesting that the stock may be undervalued.
  • Institutional investors hold about 14.04% of Sanofi's stock, reflecting confidence in the company's long-term prospects.

Cons of Sanofi

  • Sanofi's stock has experienced fluctuations, with a recent decline of about 1.1%, which may indicate volatility and uncertainty in the market.
  • Despite positive analyst ratings, the stock has not reached its 12-month high of $60.12 recently, suggesting potential challenges in gaining upward momentum.
  • Some hedge funds, like DAVENPORT & Co LLC, have reduced their positions in Sanofi, which could signal a lack of confidence among certain investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$118.01 billion
P/E Ratio
17.33
Consensus Rating
Buy
Consensus Price Target
$61.50 (+26.8% Upside)
Volume
1.62 million shares
Average Volume
2.32 million shares
Today's Range
$48.32
$48.75
50-Day Range
$47.62
$52.90
52-Week Range
$45.80
$60.12
Dividend Yield
3.29%
Medtronic stock logo

20. Medtronic NYSE:MDT

$89.74 +0.52 (+0.58%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$89.48 -0.27 (-0.30%)
As of 04:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $89.39, which is near the midpoint of its 52-week range, indicating potential for growth.
  • Medtronic plc recently reported strong quarterly earnings, with earnings per share (EPS) of $1.62, surpassing analysts' expectations, which reflects solid financial performance.
  • The company has a healthy dividend yield of 3.18%, providing investors with a steady income stream, which is attractive in a low-interest-rate environment.

Cons of Medtronic

  • The company has a relatively high dividend payout ratio of 78.45%, which may raise concerns about sustainability if earnings do not continue to grow.
  • Despite positive earnings, the stock has a P/E ratio of 24.69, which may indicate that it is overvalued compared to its earnings potential.
  • Some analysts have issued neutral ratings, suggesting that there may be limited upside potential in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$114.43 billion
P/E Ratio
24.79
Consensus Rating
Moderate Buy
Consensus Price Target
$98.19 (+9.4% Upside)
Volume
5.17 million shares
Average Volume
7.02 million shares
Today's Range
$89.02
$89.92
50-Day Range
$80.70
$90.02
52-Week Range
$77.94
$96.25
Dividend Yield
3.18%
Bristol Myers Squibb stock logo

21. Bristol Myers Squibb NYSE:BMY

$47.16 +0.73 (+1.58%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$47.52 +0.35 (+0.75%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The company recently reported strong earnings, with earnings per share (EPS) exceeding analysts' expectations, indicating robust financial performance.
  • Bristol-Myers Squibb has a diverse portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and other serious diseases, which can drive future growth.
  • The current stock price is around $70, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.

Cons of Bristol Myers Squibb

  • The company's quarterly revenue was down about 5.6% compared to the same period last year, which may raise concerns about its growth trajectory.
  • With a dividend payout ratio of 92.88%, there may be limited room for future dividend increases, which could affect income-focused investors.
  • Recent product performance may be impacted by competition in the biopharmaceutical market, potentially affecting future sales and market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$94.49 billion
P/E Ratio
17.66
Consensus Rating
Hold
Consensus Price Target
$57.69 (+22.3% Upside)
Volume
13.25 million shares
Average Volume
12.76 million shares
Today's Range
$46.65
$47.42
50-Day Range
$44.06
$50.68
52-Week Range
$41.20
$63.33
Dividend Yield
5.34%
HCA Healthcare stock logo

22. HCA Healthcare NYSE:HCA

$362.69 -9.11 (-2.45%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$362.60 -0.09 (-0.02%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • HCA Healthcare, Inc. reported strong earnings per share of $6.45 for the latest quarter, significantly exceeding analysts' expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue growth of 5.7%, reflecting its ability to expand and adapt in the healthcare market.
  • With a current stock price around $395, HCA Healthcare, Inc. is positioned within a favorable range compared to its 52-week high of $417.14, suggesting potential for appreciation.

Cons of HCA Healthcare

  • The stock has a relatively high P/E ratio of 16.82, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • HCA Healthcare, Inc. has a high debt-to-equity ratio of 69.07, suggesting that the company relies heavily on debt financing, which could pose risks in a rising interest rate environment.
  • Recent insider selling, including a significant transaction by the COO, may raise concerns about the company's future prospects and insider confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$89.45 billion
P/E Ratio
16.13
Consensus Rating
Moderate Buy
Consensus Price Target
$399.21 (+10.1% Upside)
Volume
2.00 million shares
Average Volume
1.45 million shares
Today's Range
$354.94
$365.82
50-Day Range
$353.85
$389.81
52-Week Range
$289.98
$417.14
Dividend Yield
0.77%
McKesson stock logo

23. McKesson NYSE:MCK

$715.57 +4.75 (+0.67%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$710.27 -5.30 (-0.74%)
As of 07/16/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $708, reflecting a strong market position and investor confidence in the company's future growth.
  • Recent upgrades from multiple analysts, including UBS Group and Bank of America, have raised price targets significantly, indicating positive market sentiment.
  • McKesson Co. has a robust market capitalization of approximately $88.64 billion, showcasing its stability and potential for long-term growth.

Cons of McKesson

  • Insider selling has been notable, with executives selling over 33,000 shares recently, which may raise concerns about their confidence in the company's future performance.
  • The stock has experienced fluctuations, with a recent drop of about 5% during trading, indicating potential volatility that could affect short-term investors.
  • Despite a strong market position, the company faces competition in the healthcare sector, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$88.93 billion
P/E Ratio
27.70
Consensus Rating
Moderate Buy
Consensus Price Target
$710.17 (-0.8% Downside)
Volume
418,188 shares
Average Volume
922,333 shares
Today's Range
$707.17
$715.99
50-Day Range
$682.20
$735.41
52-Week Range
$464.42
$737.89
Dividend Yield
0.40%
CVS Health stock logo

24. CVS Health NYSE:CVS

$63.80 -0.14 (-0.23%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$64.04 +0.25 (+0.39%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • The company reported strong earnings per share of $2.25 for the latest quarter, significantly exceeding analyst expectations, which indicates robust financial performance.
  • CVS Health Co. achieved a revenue of approximately $94.59 billion, surpassing forecasts, showcasing its ability to grow and capture market share.
  • The current stock price is around $75, reflecting a positive market sentiment and potential for further appreciation.

Cons of CVS Health

  • Despite recent growth, CVS Health Co. has a relatively low net margin of 1.39%, which may indicate challenges in profitability compared to competitors.
  • The company's return on equity stands at 10.59%, which, while positive, may not be as high as some investors would prefer in a competitive market.
  • Insider ownership is only about 1.22%, which could suggest a lack of confidence from those closest to the company regarding its future prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$80.89 billion
P/E Ratio
15.23
Consensus Rating
Moderate Buy
Consensus Price Target
$75.38 (+18.2% Upside)
Volume
5.83 million shares
Average Volume
10.73 million shares
Today's Range
$63.73
$64.71
50-Day Range
$60.03
$69.56
52-Week Range
$43.56
$72.51
Dividend Yield
4.16%
Cigna Group stock logo

25. Cigna Group NYSE:CI

$305.71 +3.28 (+1.08%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$305.83 +0.12 (+0.04%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group has received multiple upgrades from analysts, with recent price targets set between $362.00 and $390.00, indicating strong market confidence in the company's growth potential.
  • The current stock price is around $304.87, which may present a buying opportunity for investors looking for value in a well-rated stock.
  • The company reported impressive quarterly earnings, exceeding expectations with an EPS of $6.74, showcasing its strong financial performance and ability to generate profit.

Cons of Cigna Group

  • The stock has experienced volatility, recently trading down about 1.3%, which may concern investors looking for stability in their portfolios.
  • Despite strong earnings, the company has a relatively low net margin of 1.97%, indicating that profit generation may be constrained compared to its revenue.
  • The Cigna Group's debt-to-equity ratio stands at 0.65, which, while manageable, suggests that the company is somewhat reliant on debt financing, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$80.79 billion
P/E Ratio
16.93
Consensus Rating
Buy
Consensus Price Target
$380.39 (+24.4% Upside)
Volume
1.42 million shares
Average Volume
1.73 million shares
Today's Range
$300.01
$306.46
50-Day Range
$301.90
$334.71
52-Week Range
$262.03
$370.83
Dividend Yield
2.00%
GSK stock logo

26. GSK NYSE:GSK

$38.26 +0.44 (+1.17%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$38.15 -0.11 (-0.30%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $38.26, which may present a buying opportunity for investors looking for value.
  • GSK plc recently reported strong earnings, with earnings per share exceeding expectations, indicating robust financial performance.
  • The company has increased its quarterly dividend to $0.4216, reflecting a commitment to returning value to shareholders and a healthy dividend yield of approximately 4.41%.

Cons of GSK

  • One research analyst has rated GSK plc with a "sell" rating, which may indicate potential concerns about the stock's future performance.
  • GSK plc has a relatively high debt-to-equity ratio of 1.21, suggesting that the company relies significantly on debt financing, which can be risky in volatile markets.
  • The stock has experienced fluctuations, with a 12-month high of $44.67 and a low of $31.72, indicating potential volatility that could deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$77.43 billion
P/E Ratio
19.72
Consensus Rating
Hold
Consensus Price Target
$37.38 (-2.3% Downside)
Volume
6.32 million shares
Average Volume
5.01 million shares
Today's Range
$37.87
$38.58
50-Day Range
$36.25
$42.50
52-Week Range
$31.72
$44.67
Dividend Yield
4.52%
Elevance Health stock logo

27. Elevance Health NYSE:ELV

$344.51 +8.30 (+2.47%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$345.00 +0.49 (+0.14%)
As of 04:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$75.96 billion
P/E Ratio
13.44
Consensus Rating
Moderate Buy
Consensus Price Target
$481.87 (+39.9% Upside)
Volume
2.49 million shares
Average Volume
1.63 million shares
Today's Range
$336.20
$346.36
50-Day Range
$336.06
$416.87
52-Week Range
$335.17
$567.26
Dividend Yield
2.03%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$151.46 -1.40 (-0.92%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$151.72 +0.26 (+0.17%)
As of 04:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $156, which reflects a solid position in the market and potential for growth.
  • Recent institutional investments indicate strong confidence in Zoetis Inc., with 92.80% of the stock owned by institutional investors and hedge funds.
  • Zoetis Inc. has shown significant growth in holdings by major investors, such as Edgestream Partners L.P., which increased its stake by 466.4% recently, suggesting strong future prospects.

Cons of Zoetis

  • Despite the positive outlook, the stock has experienced fluctuations, with a fifty-two week high of $200.33 and a low of $139.70, indicating volatility.
  • Some analysts have downgraded their ratings, with Stifel Nicolaus lowering Zoetis from a "buy" to a "hold," which may signal caution among investors.
  • Insider selling, such as the recent sale of 652 shares by an executive vice president, could raise concerns about the company's short-term outlook.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$68.05 billion
P/E Ratio
27.19
Consensus Rating
Buy
Consensus Price Target
$212.13 (+40.1% Upside)
Volume
3.96 million shares
Average Volume
2.59 million shares
Today's Range
$150.94
$154.01
50-Day Range
$151.46
$170.40
52-Week Range
$139.70
$200.33
Dividend Yield
1.31%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$547.93 -0.03 (-0.01%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$555.10 +7.17 (+1.31%)
As of 04:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $545, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Regeneron Pharmaceuticals, Inc. has a strong consensus rating of "Moderate Buy" from analysts, indicating positive sentiment towards the stock.
  • The company has a solid market capitalization of approximately $58.84 billion, reflecting its significant presence and stability in the industry.

Cons of Regeneron Pharmaceuticals

  • The company recently missed earnings expectations, reporting $8.22 per share compared to the consensus estimate of $8.83, which may raise concerns about its financial performance.
  • Regeneron Pharmaceuticals, Inc. experienced a year-over-year revenue decline of 3.7%, indicating potential challenges in maintaining growth.
  • Several analysts have downgraded their price targets for the stock, with some setting targets as low as $560, suggesting a cautious outlook on its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$59.16 billion
P/E Ratio
13.95
Consensus Rating
Moderate Buy
Consensus Price Target
$814.57 (+48.7% Upside)
Volume
1.09 million shares
Average Volume
918,475 shares
Today's Range
$546.57
$558.35
50-Day Range
$483.07
$614.79
52-Week Range
$476.49
$1,211.20
Dividend Yield
0.64%
Cencora stock logo

30. Cencora NYSE:COR

$297.83 +3.18 (+1.08%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$293.98 -3.85 (-1.29%)
As of 04:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $297, reflecting a strong market presence and potential for growth.
  • Recent analyst upgrades indicate positive sentiment, with several firms raising their target prices significantly, suggesting confidence in the company's future performance.
  • Institutional ownership is high at approximately 97.52%, which often indicates strong confidence from large investors in the company's stability and growth prospects.

Cons of Cencora

  • The stock has experienced fluctuations, with a recent decline of about 0.9%, which may indicate volatility and uncertainty in the market.
  • High debt-to-equity ratio of 6.01 suggests that the company is heavily leveraged, which can pose risks during economic downturns or if cash flow becomes constrained.
  • Despite recent upgrades, some analysts still maintain a hold rating, indicating that not all market participants are convinced of the stock's upside potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$57.11 billion
P/E Ratio
34.55
Consensus Rating
Moderate Buy
Consensus Price Target
$309.83 (+4.0% Upside)
Volume
1.32 million shares
Average Volume
1.50 million shares
Today's Range
$293.81
$298.21
50-Day Range
$278.35
$302.43
52-Week Range
$218.65
$309.35
Dividend Yield
0.75%
Becton, Dickinson and Company stock logo

31. Becton, Dickinson and Company NYSE:BDX

$178.23 -0.08 (-0.05%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$178.19 -0.04 (-0.02%)
As of 04:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $175, which may present a buying opportunity for investors looking for value in the medical supply sector.
  • Institutional ownership is high, with 86.97% of the stock held by institutional investors, indicating strong confidence in the company's future performance.
  • Becton, Dickinson and Company has a solid market capitalization of approximately $50.26 billion, suggesting stability and a strong position in the healthcare market.

Cons of Becton, Dickinson and Company

  • Recent downgrades from multiple analysts, including Wells Fargo and Piper Sandler, suggest a cautious outlook on the stock's performance.
  • The stock has experienced fluctuations, with a 52-week high of $251.99 and a low of $163.33, indicating potential volatility that could concern risk-averse investors.
  • Analysts have adjusted target prices downward, reflecting a more conservative view on future growth potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.10 billion
P/E Ratio
34.01
Consensus Rating
Hold
Consensus Price Target
$219.22 (+23.0% Upside)
Volume
4.16 million shares
Average Volume
2.12 million shares
Today's Range
$175.97
$179.11
50-Day Range
$167.22
$178.46
52-Week Range
$163.33
$251.99
Dividend Yield
2.33%
Takeda Pharmaceutical stock logo

32. Takeda Pharmaceutical NYSE:TAK

$14.72 -0.04 (-0.24%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$14.75 +0.03 (+0.23%)
As of 04:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $14.67, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Recent institutional investments, such as Vontobel Holding Ltd. acquiring a stake valued at approximately $262,000, indicate growing confidence in the company's future performance.
  • Takeda Pharmaceutical Company Limited has shown resilience with a market capitalization of $46.68 billion, suggesting stability and potential for growth in the competitive pharmaceutical market.

Cons of Takeda Pharmaceutical

  • The company reported earnings per share of $0.16, which fell short of the consensus estimate of $0.24, raising concerns about its profitability and ability to meet market expectations.
  • Takeda Pharmaceutical Company Limited has a net margin of only 2.36%, indicating that its profitability may be under pressure, which could affect future earnings growth.
  • Despite recent investments, only 9.17% of the stock is owned by institutional investors and hedge funds, suggesting a lack of widespread institutional confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.93 billion
P/E Ratio
66.89
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
3.60 million shares
Average Volume
2.01 million shares
Today's Range
$14.63
$14.75
50-Day Range
$13.69
$15.55
52-Week Range
$12.80
$15.53
Dividend Yield
3.74%
Veeva Systems stock logo

33. Veeva Systems NYSE:VEEV

$282.35 +3.03 (+1.09%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$281.82 -0.53 (-0.19%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $284.50, reflecting a stable market position and potential for growth.
  • Veeva Systems Inc. reported a significant increase in revenue, with a year-over-year growth of 16.7%, indicating strong demand for its cloud-based software solutions in the life sciences sector.
  • The company has a solid earnings performance, with earnings per share (EPS) of $1.97, surpassing analysts' expectations, which suggests effective management and operational efficiency.

Cons of Veeva Systems

  • Insider selling has been observed, with recent transactions showing a 4.43% decrease in ownership by insiders, which may raise concerns about their confidence in the company's future performance.
  • The stock has experienced fluctuations, with a one-year high of $291.69 and a low of $177.41, indicating potential volatility that could affect investment stability.
  • The price-to-earnings (P/E) ratio stands at 60.27, which is relatively high, suggesting that the stock may be overvalued compared to its earnings, potentially limiting future price appreciation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.64 billion
P/E Ratio
59.82
Consensus Rating
Moderate Buy
Consensus Price Target
$274.17 (-2.9% Downside)
Volume
655,300 shares
Average Volume
1.17 million shares
Today's Range
$278.66
$282.47
50-Day Range
$233.41
$289.99
52-Week Range
$177.41
$291.69
Dividend Yield
N/A
Edwards Lifesciences stock logo

34. Edwards Lifesciences NYSE:EW

$76.15 -0.66 (-0.86%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$76.85 +0.70 (+0.92%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The company recently reported earnings per share (EPS) of $0.64, exceeding expectations, which indicates strong financial performance and potential for growth.
  • Edwards Lifesciences Co. has a high net margin of 75.48%, suggesting that it retains a significant portion of revenue as profit, which can be attractive for investors looking for profitability.
  • The current stock price is around $76, which is above its 50-day simple moving average of $76.12, indicating a potential upward trend in stock performance.

Cons of Edwards Lifesciences

  • Insider selling has been notable, with executives selling a total of over 40,000 shares recently, which could signal a lack of confidence in the stock's future performance.
  • The CFO's recent sale of shares represents a 21.49% decrease in their ownership, which may raise concerns about the company's future direction.
  • Despite strong earnings, the EPS has decreased from $0.66 in the same quarter last year, indicating potential challenges in maintaining growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.06 billion
P/E Ratio
10.88
Consensus Rating
Hold
Consensus Price Target
$81.00 (+6.4% Upside)
Volume
5.07 million shares
Average Volume
5.25 million shares
Today's Range
$75.30
$77.04
50-Day Range
$73.31
$78.79
52-Week Range
$58.93
$88.61
Dividend Yield
N/A
Haleon stock logo

35. Haleon NYSE:HLN

$9.70 -0.04 (-0.36%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$9.67 -0.02 (-0.22%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $10.39, which may present a buying opportunity for investors looking for value.
  • Haleon plc has received multiple upgrades from analysts, including a recent upgrade to "outperform" with a price target of $13.40, indicating positive market sentiment.
  • The company has a solid market capitalization of approximately $46.70 billion, suggesting stability and potential for growth.

Cons of Haleon

  • The stock has experienced a slight decline of about 0.3% recently, which may indicate short-term volatility.
  • Haleon plc has a relatively high P/E ratio of 26.63, which could suggest that the stock is overvalued compared to its earnings.
  • The company has a quick ratio of 0.78, indicating that it may have some challenges in meeting short-term liabilities without selling inventory.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.71 billion
P/E Ratio
24.86
Consensus Rating
Moderate Buy
Consensus Price Target
$12.33 (+27.1% Upside)
Volume
11.25 million shares
Average Volume
9.70 million shares
Today's Range
$9.67
$9.77
50-Day Range
$9.70
$11.42
52-Week Range
$8.80
$11.42
Dividend Yield
2.52%
Alcon stock logo

36. Alcon NYSE:ALC

$86.87 +0.92 (+1.08%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$86.57 -0.30 (-0.35%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $91.50, reflecting a strong performance in the market.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a growth trend that may attract investors.
  • Institutional ownership is significant, with a high percentage indicating confidence from large investors.

Cons of Alcon

  • Despite recent positive trends, the average daily volume has decreased, which may indicate reduced trading interest.
  • The month-to-month change in shares shorted has shown fluctuations, which could signal uncertainty in the stock's future performance.
  • While institutional ownership is high, it remains below 1, suggesting that there may be room for improvement in attracting larger investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.39 billion
P/E Ratio
38.61
Consensus Rating
Moderate Buy
Consensus Price Target
$106.13 (+22.2% Upside)
Volume
2.35 million shares
Average Volume
1.22 million shares
Today's Range
$85.52
$87.63
50-Day Range
$84.77
$95.85
52-Week Range
$80.48
$101.10
Dividend Yield
N/A
IDEXX Laboratories stock logo

37. IDEXX Laboratories NASDAQ:IDXX

$520.57 -6.09 (-1.16%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$520.42 -0.15 (-0.03%)
As of 07/16/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • IDEXX Laboratories, Inc. reported earnings per share (EPS) of $2.96 for the latest quarter, exceeding expectations, which indicates strong financial performance and potential for growth.
  • The company has shown a solid return on equity of 57.35%, suggesting effective management and profitability, which can be attractive to investors looking for efficient use of equity.
  • Recent revenue growth of 3.6% compared to the same quarter last year reflects the company's ability to expand its market presence and maintain sales momentum.

Cons of IDEXX Laboratories

  • Insider selling activity, such as the recent sale of shares by a director, may raise concerns about the company's future prospects and could indicate a lack of confidence from those within the organization.
  • The stock has experienced fluctuations, with a recent decline of about 1.8%, which may suggest volatility and potential risks for investors.
  • Despite positive earnings, the company's net margin of 22.76% may not be as high as some investors expect, indicating potential challenges in maintaining profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.36 billion
P/E Ratio
48.11
Consensus Rating
Moderate Buy
Consensus Price Target
$558.11 (+7.2% Upside)
Volume
471,824 shares
Average Volume
645,843 shares
Today's Range
$506.91
$521.27
50-Day Range
$489.98
$546.31
52-Week Range
$356.14
$549.52
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

38. Alnylam Pharmaceuticals NASDAQ:ALNY

$322.81 +11.69 (+3.76%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$322.95 +0.14 (+0.04%)
As of 07/16/2025 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The current stock price is around $331.94, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Alnylam Pharmaceuticals, Inc. has shown a significant year-over-year revenue growth of over 20%, suggesting strong demand for its products and potential for future profitability.
  • Analysts have a consensus rating of "Moderate Buy" for Alnylam Pharmaceuticals, Inc., with a price target of $340.00, indicating confidence in the company's future performance.

Cons of Alnylam Pharmaceuticals

  • The company reported a negative earnings per share (EPS) of around -0.44, which is below analysts' expectations, indicating potential challenges in achieving profitability.
  • Alnylam Pharmaceuticals, Inc. has a high debt-to-equity ratio, suggesting that it relies heavily on debt financing, which can be risky if market conditions change.
  • Insider selling activity, including a significant sale by the CEO, may raise concerns about the company's future outlook and management's confidence in its performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.57 billion
P/E Ratio
-154.45
Consensus Rating
Moderate Buy
Consensus Price Target
$346.13 (+7.2% Upside)
Volume
1.23 million shares
Average Volume
855,449 shares
Today's Range
$311.26
$323.41
50-Day Range
$252.00
$331.94
52-Week Range
$205.87
$333.70
Dividend Yield
N/A
Cardinal Health stock logo

39. Cardinal Health NYSE:CAH

$161.07 +0.05 (+0.03%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$161.76 +0.69 (+0.43%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $162, reflecting a strong performance in the market.
  • Recent upgrades from multiple analysts, including a target price increase to $179, indicate positive market sentiment and potential for growth.
  • Cardinal Health, Inc. has consistently reported earnings that exceed analysts' expectations, showcasing its strong financial health and operational efficiency.

Cons of Cardinal Health

  • The company has a negative return on equity, which may raise concerns about its ability to generate profit from shareholders' investments.
  • Despite recent revenue growth, the company reported a net margin of only 0.70%, indicating potential challenges in profitability.
  • Analysts have mixed ratings, with some holding a neutral stance, suggesting uncertainty about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$38.43 billion
P/E Ratio
25.13
Consensus Rating
Moderate Buy
Consensus Price Target
$158.07 (-1.9% Downside)
Volume
1.35 million shares
Average Volume
2.23 million shares
Today's Range
$160.20
$161.82
50-Day Range
$147.14
$167.92
52-Week Range
$94.29
$168.44
Dividend Yield
1.27%
ResMed stock logo

40. ResMed NYSE:RMD

$254.00 +1.99 (+0.79%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$254.90 +0.90 (+0.36%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The current stock price is around $38.05 billion in market capitalization, indicating a strong position in the medical equipment sector.
  • ResMed Inc. reported a quarterly earnings per share (EPS) of $2.37, exceeding analysts' expectations, which reflects strong financial performance and potential for growth.
  • The company has a solid net margin of 26.15%, suggesting effective cost management and profitability, which can lead to higher returns for investors.

Cons of ResMed

  • The price-to-earnings ratio of 29.12 may suggest that the stock is overvalued compared to its earnings, which could deter value-focused investors.
  • Despite a strong performance, the dividend yield is relatively low at 0.83%, which may not attract income-focused investors looking for higher returns from dividends.
  • The company's beta of 0.77 indicates lower volatility compared to the market, which might not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.95 billion
P/E Ratio
28.51
Consensus Rating
Moderate Buy
Consensus Price Target
$263.00 (+3.5% Upside)
Volume
829,576 shares
Average Volume
964,359 shares
Today's Range
$250.18
$254.45
50-Day Range
$243.03
$258.24
52-Week Range
$196.43
$263.05
Dividend Yield
0.84%
GE HealthCare Technologies stock logo

41. GE HealthCare Technologies NASDAQ:GEHC

$75.45 +1.06 (+1.42%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$75.50 +0.05 (+0.07%)
As of 07/16/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company recently reported earnings per share (EPS) of $1.01, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • GE HealthCare Technologies Inc. has a robust revenue stream, with quarterly revenue reaching approximately $4.78 billion, showcasing its solid market position and demand for its products and services.
  • The firm has announced a stock buyback program worth $1.00 billion, which often signals that the company's leadership believes its shares are undervalued, potentially leading to an increase in stock price.

Cons of GE HealthCare Technologies

  • Despite recent positive earnings, the stock has seen price target reductions from several analysts, indicating potential concerns about future performance.
  • The dividend yield is relatively low at 0.19%, which may not be attractive for income-focused investors looking for higher returns from dividends.
  • Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy," suggesting that there may be uncertainty about its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.06 billion
P/E Ratio
15.88
Consensus Rating
Moderate Buy
Consensus Price Target
$88.55 (+17.4% Upside)
Volume
6.40 million shares
Average Volume
3.55 million shares
Today's Range
$74.20
$76.21
50-Day Range
$69.16
$76.50
52-Week Range
$57.65
$94.80
Dividend Yield
0.19%
argenex stock logo

42. argenex NASDAQ:ARGX

$577.92 +21.96 (+3.95%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$573.62 -4.30 (-0.74%)
As of 04:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The company recently reported earnings per share of $2.58, surpassing expectations, which indicates strong financial performance and potential for growth.
  • argenx SE has a high net margin of 40.20%, suggesting efficient management and profitability, which can be attractive to investors looking for financially sound companies.
  • With a current stock price around $543, the stock has shown resilience and potential for appreciation, especially given its recent trading activity.

Cons of argenex

  • The stock has experienced fluctuations, with a one-year high of $678.21 and a low of $432.96, indicating volatility that may concern risk-averse investors.
  • Despite strong earnings, the company operates in a competitive biotechnology sector, which can pose risks related to market share and innovation.
  • Recent analyst reports have shown mixed ratings, with some analysts maintaining a "hold" rating, suggesting caution among certain market experts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.02 billion
P/E Ratio
35.65
Consensus Rating
Buy
Consensus Price Target
$728.06 (+26.0% Upside)
Volume
464,676 shares
Average Volume
332,210 shares
Today's Range
$558.34
$578.32
50-Day Range
$532.27
$587.61
52-Week Range
$457.42
$678.21
Dividend Yield
N/A
DexCom stock logo

43. DexCom NASDAQ:DXCM

$84.13 -0.65 (-0.77%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$84.50 +0.37 (+0.44%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The company reported a revenue increase of 12.5% year-over-year, indicating strong growth potential in the medical device market.
  • DexCom, Inc. has a robust return on equity of 30.05%, suggesting effective management and profitability in generating returns for shareholders.
  • The current stock price is around $84, which may present a buying opportunity for investors looking to enter at a favorable valuation.

Cons of DexCom

  • The company missed analysts' EPS estimates by $0.01, which may raise concerns about its ability to meet market expectations consistently.
  • Insider selling activity has been noted, with executives selling a total of 27,190 shares recently, which could signal a lack of confidence in the stock's short-term performance.
  • The stock has a high price-to-earnings (P/E) ratio of 61.74, indicating that it may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.24 billion
P/E Ratio
62.78
Consensus Rating
Moderate Buy
Consensus Price Target
$99.60 (+18.4% Upside)
Volume
2.35 million shares
Average Volume
4.41 million shares
Today's Range
$83.85
$85.57
50-Day Range
$79.84
$87.57
52-Week Range
$57.52
$117.19
Dividend Yield
N/A
Agilent Technologies stock logo

44. Agilent Technologies NYSE:A

$113.44 +0.50 (+0.44%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$113.74 +0.30 (+0.26%)
As of 04:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $121, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Agilent Technologies, Inc. reported strong quarterly earnings, exceeding analysts' expectations with a revenue of $1.67 billion, showcasing robust financial performance.
  • The company has a solid market capitalization of $34.40 billion, indicating its significant presence and stability in the market.

Cons of Agilent Technologies

  • The price-to-earnings (P/E) ratio of 29.90 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Agilent Technologies, Inc. has a beta of 1.23, indicating higher volatility compared to the market, which may pose risks for conservative investors.
  • Despite recent growth, the company has a price-to-earnings-growth (P/E/G) ratio of 3.68, which may indicate that the stock is expensive relative to its growth rate.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.08 billion
P/E Ratio
28.01
Consensus Rating
Moderate Buy
Consensus Price Target
$139.77 (+23.2% Upside)
Volume
2.25 million shares
Average Volume
1.86 million shares
Today's Range
$111.86
$114.46
50-Day Range
$106.93
$124.18
52-Week Range
$96.43
$153.84
Dividend Yield
0.88%
BeOne Medicines stock logo

45. BeOne Medicines NASDAQ:ONC

$279.16 +9.46 (+3.51%)
As of 07/16/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$29.56 billion
P/E Ratio
-75.04
Consensus Rating
Buy
Consensus Price Target
$324.89 (+16.4% Upside)
Volume
489,237 shares
Average Volume
302,639 shares
Today's Range
$272.22
$279.88
50-Day Range
$219.95
$279.16
52-Week Range
$148.81
$287.88
Dividend Yield
N/A
IQVIA stock logo

46. IQVIA NYSE:IQV

$158.74 +1.06 (+0.67%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$158.00 -0.74 (-0.47%)
As of 04:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $161.62, which may present a buying opportunity for investors looking for value in the medical research sector.
  • IQVIA Holdings Inc. reported a quarterly earnings per share of $2.70, exceeding analysts' expectations, indicating strong financial performance and potential for growth.
  • The company has shown a year-over-year revenue increase of 2.5%, suggesting resilience and the ability to grow even in challenging market conditions.

Cons of IQVIA

  • Recent downgrades from several brokerages, including HSBC and Mizuho, have lowered price targets significantly, which may indicate a bearish outlook on the stock's performance.
  • The stock has experienced volatility, with a twelve-month high of $252.88 and a low of $134.65, suggesting potential risks for investors regarding price stability.
  • IQVIA Holdings Inc. has a relatively high debt-to-equity ratio of 2.19, which may raise concerns about the company's financial leverage and risk profile.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.28 billion
P/E Ratio
21.63
Consensus Rating
Moderate Buy
Consensus Price Target
$222.45 (+40.1% Upside)
Volume
1.50 million shares
Average Volume
1.66 million shares
Today's Range
$156.16
$159.80
50-Day Range
$136.96
$165.53
52-Week Range
$134.65
$252.88
Dividend Yield
N/A
Humana stock logo

47. Humana NYSE:HUM

$226.62 +4.72 (+2.12%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$225.50 -1.12 (-0.49%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $229, which may present a buying opportunity for investors looking for value.
  • Humana Inc. recently reported strong quarterly earnings, with earnings per share surpassing analysts' expectations, indicating robust financial performance.
  • The company has a solid market capitalization of approximately $27.75 billion, reflecting its significant presence in the insurance sector.

Cons of Humana

  • The stock has experienced volatility, with a 52-week high of $406.46 and a low of $212.45, indicating potential risks associated with price fluctuations.
  • Despite recent upgrades from analysts, the average rating remains a "Hold," suggesting that there may not be strong bullish sentiment in the market.
  • The company's debt-to-equity ratio stands at 0.71, which, while manageable, indicates that it has a moderate level of debt that could impact financial stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.78 billion
P/E Ratio
16.03
Consensus Rating
Hold
Consensus Price Target
$279.81 (+23.5% Upside)
Volume
1.10 million shares
Average Volume
1.81 million shares
Today's Range
$221.21
$227.34
50-Day Range
$221.99
$255.23
52-Week Range
$212.45
$406.46
Dividend Yield
1.60%
BioNTech stock logo

48. BioNTech NASDAQ:BNTX

$112.49 +1.84 (+1.66%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$112.41 -0.08 (-0.07%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More about BioNTech

Pros of BioNTech

  • The current stock price is around $102, which is significantly lower than its 52-week high, indicating potential for growth.
  • BioNTech SE has a strong financial position, with a quick ratio of 10.02 and a current ratio of 10.18, suggesting excellent liquidity and ability to meet short-term obligations.
  • The company has a low debt-to-equity ratio of 0.01, indicating minimal reliance on debt for financing, which can be attractive to risk-averse investors.

Cons of BioNTech

  • The company has a negative P/E ratio of -31.74, indicating that it is currently not profitable, which can be a red flag for potential investors.
  • Trading volumes have been lower than average, which may indicate reduced investor interest or liquidity issues in the stock.
  • Despite a strong market cap of approximately $25.94 billion, the stock has experienced significant volatility, which can pose risks for investors looking for stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.60 billion
P/E Ratio
-33.09
Consensus Rating
Moderate Buy
Consensus Price Target
$136.58 (+21.4% Upside)
Volume
786,508 shares
Average Volume
939,223 shares
Today's Range
$109.07
$112.55
50-Day Range
$92.08
$115.64
52-Week Range
$76.53
$131.49
Dividend Yield
N/A
Mettler-Toledo International stock logo

49. Mettler-Toledo International NYSE:MTD

$1,183.71 +15.15 (+1.30%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$1,179.27 -4.45 (-0.38%)
As of 07/16/2025 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The current stock price is around $1,206, reflecting a strong market position and investor interest.
  • Mettler-Toledo International Inc. has a market capitalization of approximately $25.07 billion, indicating a robust financial standing and potential for growth.
  • The company reported earnings per share (EPS) of $8.19, surpassing analyst expectations, which suggests strong operational performance.

Cons of Mettler-Toledo International

  • The stock has experienced fluctuations, with a recent decline of about 1.7%, which may indicate volatility in the market.
  • Quarterly revenue was down 4.6% year-over-year, raising concerns about the company's growth trajectory and market demand.
  • The company has a high price-to-earnings (P/E) ratio of 30.09, which may suggest that the stock is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$24.29 billion
P/E Ratio
29.52
Consensus Rating
Hold
Consensus Price Target
$1,280.90 (+8.2% Upside)
Volume
202,761 shares
Average Volume
151,180 shares
Today's Range
$1,157.90
$1,186.26
50-Day Range
$1,079.96
$1,239.12
52-Week Range
$946.69
$1,546.93
Dividend Yield
N/A
Koninklijke Philips stock logo

50. Koninklijke Philips NYSE:PHG

$24.38 +0.28 (+1.14%)
Closing price 07/16/2025 03:59 PM Eastern
Extended Trading
$24.34 -0.05 (-0.18%)
As of 04:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • The current stock price is around $24, which reflects a stable position in the market.
  • Recent earnings reports showed that Koninklijke Philips exceeded analysts' expectations, indicating strong financial performance.
  • The company has a diverse business model operating in health technology, which positions it well for growth in various sectors.

Cons of Koninklijke Philips

  • The stock has experienced fluctuations, with a 12-month high of $31.57 and a low of $20.61, indicating potential volatility.
  • Recent revenue reports showed a slight decline year-over-year, which could raise concerns about growth sustainability.
  • The company has a relatively high price-to-earnings (P/E) ratio, which may suggest that the stock is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$23.22 billion
P/E Ratio
56.71
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
1.01 million shares
Average Volume
903,104 shares
Today's Range
$24.01
$24.39
50-Day Range
$22.08
$25.04
52-Week Range
$20.61
$31.57
Dividend Yield
3.41%